NasdaqCM - Nasdaq Real Time Price USD

ChromaDex Corporation (CDXC)

Compare
5.44 +0.14 (+2.64%)
At close: December 24 at 1:00:01 PM EST
5.49 +0.05 (+0.92%)
After hours: December 24 at 4:56:28 PM EST
Loading Chart for CDXC
DELL
  • Previous Close 5.30
  • Open 5.31
  • Bid 5.42 x 200
  • Ask 5.48 x 200
  • Day's Range 5.21 - 5.46
  • 52 Week Range 1.36 - 7.97
  • Volume 193,023
  • Avg. Volume 1,284,930
  • Market Cap (intraday) 415.525M
  • Beta (5Y Monthly) 1.88
  • PE Ratio (TTM) 272.00
  • EPS (TTM) 0.02
  • Earnings Date Mar 4, 2025 - Mar 10, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 7.96

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The company also commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient NIAGEN; NIAGEN as an active ingredient in its consumer products under the TRU NIAGEN name; and Immulina, a spirulina extract with predominant active compounds of Braun-type lipoproteins for supporting human immune function. In addition, it offers phytochemical reference standards, and other research and development services. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, ShopHQ, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States. ChromaDex Corporation was founded in 1999 and is headquartered in Los Angeles, California.

www.chromadex.com

106

Full Time Employees

December 31

Fiscal Year Ends

Recent News: CDXC

View More

Performance Overview: CDXC

Trailing total returns as of 12/24/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

CDXC
280.42%
S&P 500
26.63%

1-Year Return

CDXC
275.17%
S&P 500
27.03%

3-Year Return

CDXC
31.72%
S&P 500
27.81%

5-Year Return

CDXC
26.81%
S&P 500
87.35%

Compare To: CDXC

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: CDXC

View More

Valuation Measures

Annual
As of 12/24/2024
  • Market Cap

    415.52M

  • Enterprise Value

    386.17M

  • Trailing P/E

    272.00

  • Forward P/E

    41.84

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    4.53

  • Price/Book (mrq)

    12.09

  • Enterprise Value/Revenue

    4.21

  • Enterprise Value/EBITDA

    198.44

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    1.62%

  • Return on Assets (ttm)

    0.51%

  • Return on Equity (ttm)

    4.81%

  • Revenue (ttm)

    91.67M

  • Net Income Avi to Common (ttm)

    1.49M

  • Diluted EPS (ttm)

    0.02

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    32.25M

  • Total Debt/Equity (mrq)

    8.42%

  • Levered Free Cash Flow (ttm)

    4.38M

Research Analysis: CDXC

View More

Company Insights: CDXC

Research Reports: CDXC

View More

People Also Watch